Ganga Pharmaceuticals Board of Directors

Get the latest insights into the leadership at Ganga Pharmaceuticals. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Sanjay Vyankatesh Kulkarni Chairman & Non-Exe.Director
Mr. Bharat Brijmohan Sharma Managing Director & CEO
Mrs. Srijna Bharat Sharma Whole Time Director
Mr. Sachin Chandrakant Chavan Independent Director
Mr. Chetan Bhikhubhai Patel Independent Director

Ganga Pharmaceuticals Share price

GANGAPHARM

14.6

0.00 (0.00%)
Last updated on 4 Sep, 2025 | 16:00 IST
BUYSELL
Today's High

00

Today's Low

00

52 Week Low

9.25

52 Week High

19.57

The current prices are delayed, login to your account for live prices

Ganga Pharmaceuticals FAQs

The board at Ganga Pharmaceuticals consists of experienced professionals, including Mr. Sanjay Vyankatesh Kulkarni , Mr. Bharat Brijmohan Sharma , and others, overseeing the company’s strategic and corporate governance.

Directors at Ganga Pharmaceuticals are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Sanjay Vyankatesh Kulkarni is the current chairman at Ganga Pharmaceuticals.

Executive directors at Ganga Pharmaceuticals are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Ganga Pharmaceuticals adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Ganga Pharmaceuticals, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.